Twice-Yearly Shot Demonstrates Potential to End AIDS, Yet Accessibility Remains a Concern

The world is on the brink of a significant breakthrough in HIV prevention with a twice-yearly injection showing 100% effectiveness in women and nearly the same in men. Gilead, the pharmaceutical company behind this innovation, plans to offer affordable generic versions in 120 countries with high HIV rates, primarily in Africa, Southeast Asia, and the Caribbean. However, most of Latin America is excluded, raising concerns about missing a crucial chance to curb the disease.

Global Access and Concerns

Gilead's decision to exclude many Latin American countries from its generics deal has sparked criticism. Winnie Byanyima, UNAIDS executive director, praised the drug's development but stressed its importance for at-risk regions. "This is so far superior to any other prevention method we have, that it's unprecedented," she stated. The exclusion of countries like Brazil, Peru, and Argentina is seen as a missed opportunity to combat rising HIV rates.

Potential Impact on Vulnerable Groups

The twice-yearly shots could be transformative for marginalised groups who often avoid seeking care due to stigma. "It would be a miracle for these groups because it means they just have to show up twice a year at a clinic and then they're protected," Byanyima noted. In Mexico, Luis Ruvalcaba participated in the study due to fear of discrimination when asking for daily pills.

Challenges in Latin America

Dr Alma Minerva Pérez highlighted the stigma in Latin America that prevents patients from requesting daily prevention pills. She expressed hope that Mexico might eventually access generics. Health officials have not yet confirmed plans to purchase these shots for public use. Meanwhile, advocacy groups across Latin America are urging Gilead to make generics available as infection rates rise.

Cost and Production Considerations

Countries like Norway and the US pay over $40,000 annually for Sunlenca, but experts estimate generic production could reduce costs to $40 per treatment if scaled up. Dr Chris Beyrer from Duke University emphasised the importance of making these shots available in Africa and Asia while acknowledging the public health emergency posed by rising HIV rates in Latin America.

Alternative Prevention Methods

Viiv Healthcare has also limited its generics distribution in Latin America. Its bi-monthly shot Apretude is 80% to 90% effective but costs around $1,500 annually in middle-income countries. Asia Russell from Health Gap advocates for compulsory licenses to bypass patents during health crises, a strategy previously used for HIV treatments.

UNAIDS reports that AIDS-related deaths have reached their lowest since 2004, presenting an opportunity to end the epidemic. Dr Salim Abdool Karim from South Africa's University of KwaZulu-Natal remarked on the Gilead shot's unprecedented effectiveness: "The missing piece in the puzzle now is how we get it to everyone who needs it."